# OnCo record nct04414475 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04414475/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04414475", "NCT04414475" ;
  schema:name "A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac"@en ;
  schema:description "A phase 2 trial of Selinexor, Dexamethasone, Bortezomib in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04414475/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04414475> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-07-01" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/bortezomib/> ;
  onco:companies <https://onco.cc/companies/karyopharm/> .